Lilly Halts Development of Glenmark’s TRVP-1 Receptor Antagonist
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Glenmark Pharmaceuticals suffered a major blow to its drug discovery plans as Eli Lilly, its research partner for the development of pain management compound GRC 6211 suspended further clinical development on the experimental drug
You may also be interested in...
Industry Talks Painful Reality Of Drug Development At NYAS Symposium
The 2013 Dr. Paul Janssen Awards honored UCSF’s David Julius for his work in pain, but both science and industry admits pain drug development is suffering due to the complexity and cost of the research.
India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.
India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards
Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.